These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34172272)

  • 1. [New European Medicines Agency approval: Tucatinib in association with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer previously treated].
    Bonnemort J; Bellesoeur A
    Bull Cancer; 2021; 108(7-8):673-675. PubMed ID: 34172272
    [No Abstract]   [Full Text] [Related]  

  • 2. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
    N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
    DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
    Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
    Mueller V; Wardley A; Paplomata E; Hamilton E; Zelnak A; Fehrenbacher L; Jakobsen E; Curtit E; Boyle F; Harder Brix E; Brenner A; Crouzet L; Ferrario C; Muñoz-Mateu M; Arkenau HT; Iqbal N; Aithal S; Block M; Cold S; Cancel M; Hahn O; Poosarla T; Stringer-Reasor E; Colleoni M; Cameron D; Curigliano G; Siadak M; DeBusk K; Ramos J; Feng W; Gelmon K
    Eur J Cancer; 2021 Aug; 153():223-233. PubMed ID: 34214937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
    Lin NU; Borges V; Anders C; Murthy RK; Paplomata E; Hamilton E; Hurvitz S; Loi S; Okines A; Abramson V; Bedard PL; Oliveira M; Mueller V; Zelnak A; DiGiovanna MP; Bachelot T; Chien AJ; O'Regan R; Wardley A; Conlin A; Cameron D; Carey L; Curigliano G; Gelmon K; Loibl S; Mayor J; McGoldrick S; An X; Winer EP
    J Clin Oncol; 2020 Aug; 38(23):2610-2619. PubMed ID: 32468955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.
    Macpherson IR; Spiliopoulou P; Rafii S; Saggese M; Baird RD; Garcia-Corbacho J; Italiano A; Bonneterre J; Campone M; Cresti N; Posner J; Takeda Y; Arimura A; Spicer J
    Breast Cancer Res; 2019 Dec; 22(1):1. PubMed ID: 31892325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Bachelot T; Bailleux C; Darlix A; Jacot W
    Bull Cancer; 2021 Dec; 108(11S):11S26-11S34. PubMed ID: 34969513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neratinib: an option for HER2-positive metastatic breast cancer.
    O'Shaughnessy JA; O'Regan R; Isaacs C
    Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 15(9):1-20. PubMed ID: 33843838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
    Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
    Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
    Curigliano G; Mueller V; Borges V; Hamilton E; Hurvitz S; Loi S; Murthy R; Okines A; Paplomata E; Cameron D; Carey LA; Gelmon K; Hortobagyi GN; Krop I; Loibl S; Pegram M; Slamon D; Ramos J; Feng W; Winer E
    Ann Oncol; 2022 Mar; 33(3):321-329. PubMed ID: 34954044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer.
    Shah M; Wedam S; Cheng J; Fiero MH; Xia H; Li F; Fan J; Zhang X; Yu J; Song P; Chen W; Ricks TK; Chen XH; Goldberg KB; Gong Y; Pierce WF; Tang S; Theoret MR; Pazdur R; Amiri-Kordestani L; Beaver JA
    Clin Cancer Res; 2021 Mar; 27(5):1220-1226. PubMed ID: 33055172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report.
    Yan F; Rinn KJ; Kullnat JA; Wu AY; Ennett MD; Scott EL; Kaplan HG
    J Natl Compr Canc Netw; 2022 Apr; 20(7):745-752. PubMed ID: 35405660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2].
    Minot-This MS; Bellesoeur A
    Bull Cancer; 2021 Sep; 108(9):783-784. PubMed ID: 34144792
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis.
    Dong L; Lin S; Zhong L; Nian D; Li Y; Wang R; Zhou W; Weng X; Xu X
    Clin Breast Cancer; 2022 Jan; 22(1):e21-e29. PubMed ID: 34238670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.
    Madden R; Kosari S; Peterson GM; Bagheri N; Thomas J
    Int J Clin Pharmacol Ther; 2018 Feb; 56(2):72-80. PubMed ID: 29231164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tucatinib: First Approval.
    Lee A
    Drugs; 2020 Jul; 80(10):1033-1038. PubMed ID: 32548668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
    Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2-positive metastatic breast cancer: a comprehensive review.
    Exman P; Tolaney SM
    Clin Adv Hematol Oncol; 2021 Jan; 19(1):40-50. PubMed ID: 33493147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
    Tesch ME; Gelmon KA
    Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.